Although some first-in-class targeted treatments appear to enjoy a longer-term revenue advantage, this advantage is also driven by superior risk-benefit profiles rather than simply by approval timelines. Several molecular targets with few currently approved treatments may eventually become crowded with competitors attempting to carve out treatment niches by disease indication, line of treatment, and biomarker-selected subgroups.

In this one-page infographic, we provide an overview of historical revenues of cancer treatments for three major molecular targets: VEGF/VEGFR, EGFR, and Bcr-Abl (Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia).

To download the infographic, click the link at the top of the page.

For our disclosures, please read the BioMedTracker Research Standards.